about
Open Source Drug Discovery: Highly Potent Antimalarial Compounds Derived from the Tres Cantos ArylpyrrolesSpatial localisation of actin filaments across developmental stages of the malaria parasiteA long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malariaOpen Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and BeyondThe activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasitesCharacterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy ModelingPyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum.The Plasmodium berghei sexual stage antigen PSOP12 induces anti-malarial transmission blocking immunity both in vivo and in vitroAn essential role of the basal body protein SAS-6 in Plasmodium male gamete development and malaria transmissionA novel multiple-stage antimalarial agent that inhibits protein synthesisA semi-automated method for counting fluorescent malaria oocysts increases the throughput of transmission blocking studies.Hundreds of dual-stage antimalarial molecules discovered by a functional gametocyte screenA tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance.Quinolone-3-diarylethers: a new class of antimalarial drug.A male and female gametocyte functional viability assay to identify biologically relevant malaria transmission-blocking drugsQuantitative analysis of Plasmodium ookinete motion in three dimensions suggests a critical role for cell shape in the biomechanics of malaria parasite gliding motility.Changes in metabolic phenotypes of Plasmodium falciparum in vitro cultures during gametocyte developmentLead clinical and preclinical antimalarial drugs can significantly reduce sporozoite transmission to vertebrate populations.Assessment of therapeutic responses to gametocytocidal drugs in Plasmodium falciparum malariaUse of a selective inhibitor to define the chemotherapeutic potential of the plasmodial hexose transporter in different stages of the parasite's life cycleHistone methyltransferase inhibitors are orally bioavailable, fast-acting molecules with activity against different species causing malaria in humansImaging-based high-throughput screening assay to identify new molecules with transmission-blocking potential against Plasmodium falciparum female gamete formation.Use of Plasmodium falciparum culture-adapted field isolates for in vitro exflagellation-blocking assayGeneration of quinolone antimalarials targeting the Plasmodium falciparum mitochondrial respiratory chain for the treatment and prophylaxis of malariaMale and female Plasmodium falciparum mature gametocytes show different responses to antimalarial drugs.Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.Adaptation of targeted nanocarriers to changing requirements in antimalarial drug deliveryPlasmodium cell biology should inform strategies used in the development of antimalarial transmission-blocking drugs.A Malaria Transmission-Blocking (+)-Usnic Acid Derivative Prevents Plasmodium Zygote-to-Ookinete Maturation in the Mosquito Midgut.3-Hydroxy-N'-arylidenepropanehydrazonamides with Halo-Substituted Phenanthrene Scaffolds Cure P. berghei Infected Mice When Administered Perorally.Laboratory maintenance of rodent malaria parasites.Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase.Hexahydroquinolines are antimalarial candidates with potent blood-stage and transmission-blocking activity.Routine in vitro culture of P. falciparum gametocytes to evaluate novel transmission-blocking interventions.Measuring the blockade of malaria transmission--an analysis of the Standard Membrane Feeding Assay.Plasmodium male development gene-1 (mdv-1) is important for female sexual development and identifies a polarised plasma membrane during zygote development.The design and interpretation of laboratory assays measuring mosquito transmission of Plasmodium.Assessing transmission blockade in Plasmodium spp.A high-throughput assay for the identification of malarial transmission-blocking drugs and vaccines.Targeting the parasite in the mosquito: rationale and practicality.
P50
Q26883657-9E1068E7-4357-4E78-8E4A-A91D9A6CFDCDQ27308691-C8EA15EE-0B92-4B4A-A481-E853AF8F6281Q27644391-CB56BE70-0688-454D-B770-0F20E7ED6EE9Q27826351-88CC4DF2-4E64-40A8-A439-5F30D095B17CQ28480979-B6C7F457-15FA-4B32-A702-C8581CE6863CQ28554466-E75057FB-F1CA-43F7-969C-9E64A9A0C318Q28649962-69545EA2-6DC8-4E97-9670-AA5DFD11685DQ30039034-1629F06B-D3C4-4959-9F60-4BB2475F2BFBQ30039505-53CA7BAF-D55F-466B-9272-AFD811160CAEQ30044020-E43E5DDC-9F90-4514-AE43-6BDE77DB2CD8Q33670142-EA7E0B38-520B-46EB-BBAC-64BCDB53CC7DQ33720859-053BF19E-0C54-4E44-AEA7-7633686BA68DQ33761137-6846AC23-A31D-4A2B-83DF-5316CBFE6CEFQ34334269-005A31C8-F88A-4C36-84A2-7001CA814013Q34597517-0D7E00DA-EF4B-4115-B112-9ED0B624C72DQ34865705-2960E6D9-6FDE-4492-B560-957C386AEB94Q34895018-808447B3-460A-48E9-889D-0F510A46911BQ34922792-D1E9F996-A171-4639-84BC-F2A972C23B88Q34968407-773472AC-1C9D-4A9C-9B90-25D0681603B1Q35005159-58384CE7-6306-4C24-BD1B-EC8B821E8F80Q35105899-AA6A0F4A-594C-4B4B-81FC-384F259C74EDQ35584827-1D3767B1-6B14-4598-8767-E83EB9DD41D0Q35730764-6B697948-9572-412C-A1A0-5B56922951EFQ35991425-3A584C20-1D30-4177-A94E-778D130A0DC3Q36969808-BF7A8AC1-1B96-4E9A-AD7B-771537DBC867Q37412029-218D7B22-283F-4A85-98AE-CFD5A76D3420Q37675691-A2F61A19-B4F5-4A57-9B82-D42E05E892C5Q38066991-1B81E38F-2154-4D6F-BFAD-1360C0E48FBBQ38726103-440AB799-0927-420D-9CB9-4FE93F59886EQ39172819-CF8D2D0A-B859-4FAF-A7D7-2F3C7DD90D56Q39276020-BE74E008-F97A-4D40-A040-1439D84F4870Q39337756-312CCF30-B8E7-4F2B-9B70-3438D6CCDE47Q39552647-58755055-81BE-4DAE-B5B5-1916CB990EB3Q40563355-91F60477-DCE8-4127-944B-F2F3B9622C5FQ43571629-DAA112A3-A6A7-4051-A972-C360EDF7B49AQ43842129-7B28683F-28CF-4AAE-8A8E-69D1C06545D6Q44165761-314A4E06-D973-4F05-850D-2C8D4E4A5851Q44165859-57163A30-9A60-482A-9F94-8A1620C2F6AEQ44166008-ECEE5E55-F648-4EF4-A7E5-9F9CF68D3051Q47165551-154F8FAD-BB17-4663-A33A-7344683C4445
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Michael Delves
@ast
Michael Delves
@en
Michael Delves
@es
Michael Delves
@nl
Michael Delves
@sl
type
label
Michael Delves
@ast
Michael Delves
@en
Michael Delves
@es
Michael Delves
@nl
Michael Delves
@sl
altLabel
M J Delves
@en
prefLabel
Michael Delves
@ast
Michael Delves
@en
Michael Delves
@es
Michael Delves
@nl
Michael Delves
@sl
P106
P1153
15752675700
P21
P31
P496
0000-0001-8526-4782